Agenus Enrolls First Patient in Landmark BATTMAN Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy AGEN?
Agenus announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN trial. This study is evaluating Agenus' immunotherapy combination of botensilimab plus balstilimab versus best supportive care in patients with refractory, unresectable microsatellite stable/mismatch repair proficient metastatic colorectal cancer, a population long considered resistant to immunotherapy. "Enrollment of the first patient in the BATTMAN study marks a key milestone for Agenus and the BOT+BAL program," said Dr. Steven O'Day, Chief Medical Officer, Agenus. "This study advances our goal of developing effective immunotherapies for patients who currently have few options. We're grateful to our partners at CCTG, GI Cancer Trials in Australia, and PRODIGE and to the dedicated investigators, site staff, and patients driving this global effort."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGEN
Wall Street analysts forecast AGEN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.420
Low
23.00
Averages
23.00
High
23.00
Current: 4.420
Low
23.00
Averages
23.00
High
23.00
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New Therapy Shows Significant Efficacy in Gastroesophageal Cancer
- Significant Disease Control: A clinical trial for gastroesophageal cancer combining botensilimab (BOT), balstilimab (BAL), and agenT-797 demonstrated a 77% disease control rate, with long-term survival exceeding 20 months in a subset of heavily pretreated patients, indicating the potential of this combination therapy in refractory cases.
- Improved Survival Rates: Patients receiving induction therapy had a median progression-free survival (PFS) of 6.9 months compared to 3.5 months for those without induction, with a hazard ratio (HR) of 0.19 and a p-value of 0.015, underscoring the importance of immune activation and treatment sequencing.
- Enhanced Long-Term Survival: In the induction cohort, 43% of patients were alive at both 12 and 18 months, compared to only 20% and 0% in the non-induction group, highlighting the effectiveness of the induction strategy in improving long-term survival outcomes.
- Insights into Immune Mechanisms: The study revealed that the combination of BOT, BAL, and agenT-797 significantly promoted intratumoral T cell and dendritic cell infiltration, leading to the formation of organized tertiary lymphoid structures, providing crucial insights for further exploration of the biological basis of this therapy.
See More
Agenus Shows Remarkably Improving Earnings Outlook
- Earnings Estimate Revisions: Analysts have raised their earnings estimates for Agenus, projecting a quarterly EPS of $1.95, reflecting a remarkable 289.3% increase from the previous year, indicating a significant enhancement in the company's profitability that could drive further stock price appreciation.
- Zacks Rank Upgrade: Due to the positive revisions in earnings estimates, Agenus currently holds a Zacks Rank #1 (Strong Buy), a rating tool that has demonstrated an average annual return of 25% since 2008, showcasing strong investment potential.
- Full-Year Earnings Outlook: The full-year EPS estimate for Agenus stands at $1.30, representing a 151.8% increase from last year, with no negative revisions in the past month, reflecting strong analyst confidence in the company's future performance.
- Stock Price Uptrend: Over the past four weeks, Agenus's stock has risen by 14%, closely tied to the upward revisions in earnings estimates, suggesting that further upside potential remains, making it a candidate for investors to consider adding to their portfolios.
See More
Zacks Premium Empowers Confident Investing for All
- Investor Confidence Boost: Zacks Premium offers daily updates of the Zacks Rank and industry rankings, aiding investors in making more informed decisions, thereby enhancing confidence and increasing market participation.
- Style Scoring System: The Zacks Style Scores rate stocks from A to F based on value, growth, and momentum characteristics, helping investors identify the best stocks likely to outperform the market in the next 30 days, thus improving investment success rates.
- Strong Performance Returns: Since 1988, stocks with a Zacks Rank of #1 have produced an average annual return of +23.93%, more than double that of the S&P 500, demonstrating their effectiveness and reliability in portfolio construction.
- Potential Stock Recommendations: Agenus (AGEN) is rated Zacks Rank #1, with a 14% price increase over the past four weeks and an upward revision of its earnings estimate to $1.30 per share for fiscal 2026, indicating strong growth potential and warranting investor attention.
See More
Agenus Launches Landmark Global Phase 3 Clinical Trial
- Trial Launch: Agenus announced the enrollment of the first patient in the BATTMAN (CO.33) trial, evaluating the immunotherapy combination of BOT and BAL in refractory microsatellite stable metastatic colorectal cancer, aiming to enroll approximately 830 patients and complete global enrollment swiftly, reflecting unprecedented enthusiasm from investigators and patients.
- Collaborative Research Network: The trial is led by the Canadian Cancer Trials Group (CCTG) and spans over 100 sites across Canada, France, Australia, and New Zealand, aiming to provide new treatment options for difficult-to-treat patients and advance the application of immunotherapy in cold tumors.
- Clear Research Objectives: The BATTMAN trial serves as the registrational-enabling study for BOT+BAL, designed to offer effective immunotherapy solutions for this challenging patient population, potentially transforming outcomes for patients currently lacking effective treatment options.
- Historic Milestone: The enrollment of the first patient marks a significant milestone for Agenus in the immunotherapy field, with CCTG researchers optimistic about the potential survival extension from doublet immunotherapy, paving the way for future regulatory submissions.
See More
Agenus Hosts 2026 Stakeholder Webcast on Immunotherapy Progress
- Immunotherapy Progress: Agenus will host a webcast on March 31, 2026, focusing on the advancements of botensilimab and balstilimab, aiming to enhance treatment options for patients with historically treatment-resistant cancers, showcasing the company's ongoing innovation in immuno-oncology.
- Clinical Data Insights: Chief Medical Officer Steven J. O'Day will discuss the durability and consistency of BOT+BAL across various tumor types, highlighting how these data inform ongoing development and later-stage trials, indicating the company's potential in treating refractory cancers.
- Patient Access Programs: Kamel Djazouli, Head of Medical Affairs, will provide updates on Agenus' global access programs, particularly the AAC and Named Patient Programs in France, demonstrating how the company supports patients with limited treatment options, thereby enhancing its market competitiveness.
- Strategic Priorities: Founder and CEO Garo H. Armen will outline key priorities for 2026, emphasizing the urgency of advancing the BOT+BAL program to improve patient quality of life through innovative treatment solutions.
See More
Agenus Introduces Novel Immunotherapy to Extend Survival
- Innovative Immunotherapy: Agenus announced that preliminary results of the BOT and BAL combination therapy for microsatellite stable colorectal cancer will be presented at the 2026 AACR Annual Meeting, aiming to extend patient survival by reducing reliance on chemotherapy, showcasing the company's cutting-edge exploration in cancer immunotherapy.
- Clinical Trial Expansion: The BBoPCO study is the first trial assessing BOT+BAL in patients without liver, bone, or brain metastases, marking a significant shift towards early application of immunotherapy, which is expected to improve patient response and quality of life, addressing the urgent need for new treatment options.
- Market Demand: Colorectal cancer remains a leading cause of cancer-related deaths globally, with rising incidence among younger populations, and the severe side effects of traditional chemotherapy regimens highlight the critical market significance of introducing new therapies.
- Drug Mechanism: Botensilimab, as an enhanced anti-CTLA-4 antibody, combined with the PD-1 inhibition of balstilimab, aims to activate the immune system targeting traditionally
See More
New Therapy Shows Significant Efficacy in Gastroesophageal Cancer
- Significant Disease Control: A clinical trial for gastroesophageal cancer combining botensilimab (BOT), balstilimab (BAL), and agenT-797 demonstrated a 77% disease control rate, with long-term survival exceeding 20 months in a subset of heavily pretreated patients, indicating the potential of this combination therapy in refractory cases.
- Improved Survival Rates: Patients receiving induction therapy had a median progression-free survival (PFS) of 6.9 months compared to 3.5 months for those without induction, with a hazard ratio (HR) of 0.19 and a p-value of 0.015, underscoring the importance of immune activation and treatment sequencing.
- Enhanced Long-Term Survival: In the induction cohort, 43% of patients were alive at both 12 and 18 months, compared to only 20% and 0% in the non-induction group, highlighting the effectiveness of the induction strategy in improving long-term survival outcomes.
- Insights into Immune Mechanisms: The study revealed that the combination of BOT, BAL, and agenT-797 significantly promoted intratumoral T cell and dendritic cell infiltration, leading to the formation of organized tertiary lymphoid structures, providing crucial insights for further exploration of the biological basis of this therapy.
See More
Agenus Shows Remarkably Improving Earnings Outlook
- Earnings Estimate Revisions: Analysts have raised their earnings estimates for Agenus, projecting a quarterly EPS of $1.95, reflecting a remarkable 289.3% increase from the previous year, indicating a significant enhancement in the company's profitability that could drive further stock price appreciation.
- Zacks Rank Upgrade: Due to the positive revisions in earnings estimates, Agenus currently holds a Zacks Rank #1 (Strong Buy), a rating tool that has demonstrated an average annual return of 25% since 2008, showcasing strong investment potential.
- Full-Year Earnings Outlook: The full-year EPS estimate for Agenus stands at $1.30, representing a 151.8% increase from last year, with no negative revisions in the past month, reflecting strong analyst confidence in the company's future performance.
- Stock Price Uptrend: Over the past four weeks, Agenus's stock has risen by 14%, closely tied to the upward revisions in earnings estimates, suggesting that further upside potential remains, making it a candidate for investors to consider adding to their portfolios.
See More
Zacks Premium Empowers Confident Investing for All
- Investor Confidence Boost: Zacks Premium offers daily updates of the Zacks Rank and industry rankings, aiding investors in making more informed decisions, thereby enhancing confidence and increasing market participation.
- Style Scoring System: The Zacks Style Scores rate stocks from A to F based on value, growth, and momentum characteristics, helping investors identify the best stocks likely to outperform the market in the next 30 days, thus improving investment success rates.
- Strong Performance Returns: Since 1988, stocks with a Zacks Rank of #1 have produced an average annual return of +23.93%, more than double that of the S&P 500, demonstrating their effectiveness and reliability in portfolio construction.
- Potential Stock Recommendations: Agenus (AGEN) is rated Zacks Rank #1, with a 14% price increase over the past four weeks and an upward revision of its earnings estimate to $1.30 per share for fiscal 2026, indicating strong growth potential and warranting investor attention.
See More
Agenus Launches Landmark Global Phase 3 Clinical Trial
- Trial Launch: Agenus announced the enrollment of the first patient in the BATTMAN (CO.33) trial, evaluating the immunotherapy combination of BOT and BAL in refractory microsatellite stable metastatic colorectal cancer, aiming to enroll approximately 830 patients and complete global enrollment swiftly, reflecting unprecedented enthusiasm from investigators and patients.
- Collaborative Research Network: The trial is led by the Canadian Cancer Trials Group (CCTG) and spans over 100 sites across Canada, France, Australia, and New Zealand, aiming to provide new treatment options for difficult-to-treat patients and advance the application of immunotherapy in cold tumors.
- Clear Research Objectives: The BATTMAN trial serves as the registrational-enabling study for BOT+BAL, designed to offer effective immunotherapy solutions for this challenging patient population, potentially transforming outcomes for patients currently lacking effective treatment options.
- Historic Milestone: The enrollment of the first patient marks a significant milestone for Agenus in the immunotherapy field, with CCTG researchers optimistic about the potential survival extension from doublet immunotherapy, paving the way for future regulatory submissions.
See More
Agenus Hosts 2026 Stakeholder Webcast on Immunotherapy Progress
- Immunotherapy Progress: Agenus will host a webcast on March 31, 2026, focusing on the advancements of botensilimab and balstilimab, aiming to enhance treatment options for patients with historically treatment-resistant cancers, showcasing the company's ongoing innovation in immuno-oncology.
- Clinical Data Insights: Chief Medical Officer Steven J. O'Day will discuss the durability and consistency of BOT+BAL across various tumor types, highlighting how these data inform ongoing development and later-stage trials, indicating the company's potential in treating refractory cancers.
- Patient Access Programs: Kamel Djazouli, Head of Medical Affairs, will provide updates on Agenus' global access programs, particularly the AAC and Named Patient Programs in France, demonstrating how the company supports patients with limited treatment options, thereby enhancing its market competitiveness.
- Strategic Priorities: Founder and CEO Garo H. Armen will outline key priorities for 2026, emphasizing the urgency of advancing the BOT+BAL program to improve patient quality of life through innovative treatment solutions.
See More
Agenus Introduces Novel Immunotherapy to Extend Survival
- Innovative Immunotherapy: Agenus announced that preliminary results of the BOT and BAL combination therapy for microsatellite stable colorectal cancer will be presented at the 2026 AACR Annual Meeting, aiming to extend patient survival by reducing reliance on chemotherapy, showcasing the company's cutting-edge exploration in cancer immunotherapy.
- Clinical Trial Expansion: The BBoPCO study is the first trial assessing BOT+BAL in patients without liver, bone, or brain metastases, marking a significant shift towards early application of immunotherapy, which is expected to improve patient response and quality of life, addressing the urgent need for new treatment options.
- Market Demand: Colorectal cancer remains a leading cause of cancer-related deaths globally, with rising incidence among younger populations, and the severe side effects of traditional chemotherapy regimens highlight the critical market significance of introducing new therapies.
- Drug Mechanism: Botensilimab, as an enhanced anti-CTLA-4 antibody, combined with the PD-1 inhibition of balstilimab, aims to activate the immune system targeting traditionally
See More
